<p>LifeMD（納斯達克股票代碼：LFMD - 獲取免費報告）於週一發佈了其財報。該公司報告本季度每股收益為（$0.10），低於分析師一致預期的（$0.06），差距為（$0.04），據 Zacks 報道。LifeMD 更新了其 2025 財年的每股收益指引，並將 2025 年第四季度的每股收益指引進行了更新。</p>
<h2>LifeMD 股價上漲 2.2%</h2>
<ul>
<li>新任首席執行官能否振興這隻掙扎中的遠程醫療股票？</li>
</ul>
<p>週一，LifeMD 的股票在午盤交易中上漲了$0.10，達到了$4.73。該公司的股票交易量為 2,965,092 股，而其平均交易量為 1,506,321 股。該股票的 50 日移動平均為$6.07，200 日移動平均為$8.73。該公司的流動比率為 0.77，速動比率為 0.72，債務與股本比率為 9.21。該公司的市值為 2.243 億美元，市盈率為-22.52，貝塔值為 1.57。LifeMD 的 1 年最低價為$4.13，1 年最高價為$15.84。</p>
<h2>LifeMD 內部交易活動</h2>
<p>在相關消息中，內部人士 Nicholas P. Alvarez 於 9 月 10 日（星期三）出售了 75,000 股該公司的股票。該股票以平均價格$5.92 出售，總交易額為$444,000.00。出售完成後，該內部人士直接持有 605,000 股公司股票，價值約為$3,581,600。這筆交易代表其持股減少了 11.03%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。18.40% 的股票目前由公司內部人士持有。</p>
<h2>機構投資者對 LifeMD 的看法</h2>
<ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 計劃而飆升</li>
</ul>
<p>一些機構投資者最近對該股票的持倉進行了調整。Tower Research Capital LLC TRC 在第二季度將其在 LifeMD 的持股增加了 110.4%。Tower Research Capital LLC TRC 現在擁有 4,674 股該公司的股票，價值$64,000，此前在上個季度又增持了 2,452 股。Quarry LP 在第三季度購買了 LifeMD 的新股份，價值約為$52,000。Legal &amp; General Group Plc 在第二季度將其在 LifeMD 的持股增加了 187.4%。Legal &amp; General Group Plc 現在擁有 10,144 股該公司的股票，價值$138,000，此前在上個季度又購買了 6,614 股。Hudson Bay Capital Management LP 在第二季度購買了 LifeMD 的新股份，價值$153,000。最後，紐約州共同退休基金在第二季度將其在 LifeMD 的持股增加了 2,180.0%。紐約州共同退休基金現在擁有 11,400 股該公司的股票，價值$155,000，此前在該期間又增持了 10,900 股。35.52% 的股票目前由機構投資者和對沖基金持有。</p>
<h2>分析師的升級和降級</h2>
<p>幾位分析師最近對 LFMD 股票發佈了報告。華爾街 Zen 在 8 月 2 日（星期六）的一份研究報告中將 LifeMD 的股票評級從 “買入” 下調至 “持有”。Zacks Research 在 9 月 5 日（星期五）的一份研究報告中將 LifeMD 的評級從 “強烈賣出” 上調至 “持有”。KeyCorp 在 8 月 6 日（星期三）的一份研究報告中將 LifeMD 的目標價從$14.00 下調至$12.00，並對該股票給予 “增持” 評級。Lake Street Capital 在 8 月 6 日（星期三）的一份研究報告中將 LifeMD 的目標價從$18.00 下調至$14.00，並對該股票給予 “買入” 評級。最後，HC Wainwright 在 8 月 7 日（星期四）的一份研究報告中將 LifeMD 的目標價從$14.00 下調至$13.00，並對該公司給予 “買入” 評級。一位研究分析師對該股票給予了 “強烈買入” 評級，五位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價為$13.17。</p>
<ul>
<li>LifeMD 可以憑藉其 GLP-1 產品大幅上漲</li>
</ul>
<p><strong>獲取我們對 LifeMD 的最新分析</strong></p>
<h2>LifeMD 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>LifeMD, Inc 是一家直接面向患者的遠程醫療公司，連接消費者與美國的醫療專業人員以提供醫療服務。該公司提供的遠程醫療平台包括 RexMD，這是一個男性遠程醫療品牌，為各種男性健康需求提供來自持牌醫生的虛擬醫療治療；ShapiroMD 提供虛擬醫療治療、處方藥、專利醫生配方的非處方產品、外用複合藥物和治療男性和女性脱髮的醫療設備；NavaMD 是一個女性導向的遠程皮膚科，提供來自皮膚科醫生和其他提供者的虛擬醫療治療；以及處方口服和複合外用藥物用於治療衰老和痤瘡；Cleared 提供個性化的過敏、哮喘和免疫治療，包括環境和食物過敏的家庭測試、過敏和哮喘的處方以及治療慢性過敏的免疫療法。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票比 LifeMD 更好</li>
<li>消費品股票解析</li>
<li>D-Wave 與量子競爭對手在財報季後的比較</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>巴菲特減持蘋果，退休前大舉押注 Alphabet</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>三家能源巨頭提高股息——這對投資者意味着什麼</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 LifeMD 嗎？</h2>
<p>在考慮 LifeMD 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 LifeMD 並不在名單上。</p>
<p>雖然 LifeMD 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LFMD

<p>LifeMD 報告的季度每股收益為（$0.10），比市場共識預期的（$0.06）低出$0.04。儘管盈利未達預期，股價仍上漲 2.2%，至$4.73。內部人士 Nicholas Alvarez 出售了 75,000 股，減少了 11.03% 的持股比例。機構投資者增加了持股，持有該股票的比例為 35.52%。分析師的評級意見不一，市場共識目標價為$13.17。LifeMD 在美國作為一家遠程醫療公司運營</p>

<p>LifeMD (NASDAQ:LFMD - Get Free Report) issued its earnings results on Monday. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04), Zacks reports. LifeMD updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.</p>
<div class="lb-trans"><p>LifeMD（納斯達克股票代碼：LFMD - 獲取免費報告）於週一發佈了其財報。該公司報告本季度每股收益為（$0.10），低於分析師一致預期的（$0.06），差距為（$0.04），據 Zacks 報道。LifeMD 更新了其 2025 財年的每股收益指引，並將 2025 年第四季度的每股收益指引進行了更新。</p>
</div><h2>LifeMD Trading Up 2.2%</h2>
<div class="lb-trans"><h2>LifeMD 股價上漲 2.2%</h2>
</div><ul>
<li>Can the New CEO Revive This Struggling Telehealth Stock?</li>
</ul>
<div class="lb-trans"><ul>
<li>新任首席執行官能否振興這隻掙扎中的遠程醫療股票？</li>
</ul>
</div><p>LifeMD stock traded up $0.10 during mid-day trading on Monday, hitting $4.73. The company's stock had a trading volume of 2,965,092 shares, compared to its average volume of 1,506,321. The stock's fifty day moving average is $6.07 and its two-hundred day moving average is $8.73. The company has a current ratio of 0.77, a quick ratio of 0.72 and a debt-to-equity ratio of 9.21. The firm has a market capitalization of $224.30 million, a PE ratio of -22.52 and a beta of 1.57. LifeMD has a 1 year low of $4.13 and a 1 year high of $15.84.</p>
<div class="lb-trans"><p>週一，LifeMD 的股票在午盤交易中上漲了$0.10，達到了$4.73。該公司的股票交易量為 2,965,092 股，而其平均交易量為 1,506,321 股。該股票的 50 日移動平均為$6.07，200 日移動平均為$8.73。該公司的流動比率為 0.77，速動比率為 0.72，債務與股本比率為 9.21。該公司的市值為 2.243 億美元，市盈率為-22.52，貝塔值為 1.57。LifeMD 的 1 年最低價為$4.13，1 年最高價為$15.84。</p>
</div><h2>Insider Activity at LifeMD</h2>
<div class="lb-trans"><h2>LifeMD 內部交易活動</h2>
</div><p>In related news, insider Nicholas P. Alvarez sold 75,000 shares of the firm's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the sale, the insider directly owned 605,000 shares of the company's stock, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 18.40% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Nicholas P. Alvarez 於 9 月 10 日（星期三）出售了 75,000 股該公司的股票。該股票以平均價格$5.92 出售，總交易額為$444,000.00。出售完成後，該內部人士直接持有 605,000 股公司股票，價值約為$3,581,600。這筆交易代表其持股減少了 11.03%。該出售在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。18.40% 的股票目前由公司內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On LifeMD</h2>
<div class="lb-trans"><h2>機構投資者對 LifeMD 的看法</h2>
</div><ul>
<li>Hims &amp; Hers Health Soars on Generic GLP-1 Rollout Plans</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims &amp; Hers Health 因推出通用 GLP-1 計劃而飆升</li>
</ul>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its holdings in shares of LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company's stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. Quarry LP purchased a new stake in LifeMD in the third quarter valued at approximately $52,000. Legal &amp; General Group Plc lifted its stake in LifeMD by 187.4% during the second quarter. Legal &amp; General Group Plc now owns 10,144 shares of the company's stock worth $138,000 after purchasing an additional 6,614 shares in the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of LifeMD during the second quarter worth $153,000. Finally, New York State Common Retirement Fund boosted its holdings in LifeMD by 2,180.0% during the 2nd quarter. New York State Common Retirement Fund now owns 11,400 shares of the company's stock valued at $155,000 after acquiring an additional 10,900 shares during the period. 35.52% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近對該股票的持倉進行了調整。Tower Research Capital LLC TRC 在第二季度將其在 LifeMD 的持股增加了 110.4%。Tower Research Capital LLC TRC 現在擁有 4,674 股該公司的股票，價值$64,000，此前在上個季度又增持了 2,452 股。Quarry LP 在第三季度購買了 LifeMD 的新股份，價值約為$52,000。Legal &amp; General Group Plc 在第二季度將其在 LifeMD 的持股增加了 187.4%。Legal &amp; General Group Plc 現在擁有 10,144 股該公司的股票，價值$138,000，此前在上個季度又購買了 6,614 股。Hudson Bay Capital Management LP 在第二季度購買了 LifeMD 的新股份，價值$153,000。最後，紐約州共同退休基金在第二季度將其在 LifeMD 的持股增加了 2,180.0%。紐約州共同退休基金現在擁有 11,400 股該公司的股票，價值$155,000，此前在該期間又增持了 10,900 股。35.52% 的股票目前由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師的升級和降級</h2>
</div><p>Several analysts recently issued reports on LFMD shares. Wall Street Zen cut shares of LifeMD from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, August 2nd. Zacks Research upgraded LifeMD from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, September 5th. KeyCorp reduced their price objective on LifeMD from $14.00 to $12.00 and set an &#34;overweight&#34; rating on the stock in a research report on Wednesday, August 6th. Lake Street Capital lowered their price objective on LifeMD from $18.00 to $14.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, August 6th. Finally, HC Wainwright cut their target price on LifeMD from $14.00 to $13.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $13.17.</p>
<div class="lb-trans"><p>幾位分析師最近對 LFMD 股票發佈了報告。華爾街 Zen 在 8 月 2 日（星期六）的一份研究報告中將 LifeMD 的股票評級從 “買入” 下調至 “持有”。Zacks Research 在 9 月 5 日（星期五）的一份研究報告中將 LifeMD 的評級從 “強烈賣出” 上調至 “持有”。KeyCorp 在 8 月 6 日（星期三）的一份研究報告中將 LifeMD 的目標價從$14.00 下調至$12.00，並對該股票給予 “增持” 評級。Lake Street Capital 在 8 月 6 日（星期三）的一份研究報告中將 LifeMD 的目標價從$18.00 下調至$14.00，並對該股票給予 “買入” 評級。最後，HC Wainwright 在 8 月 7 日（星期四）的一份研究報告中將 LifeMD 的目標價從$14.00 下調至$13.00，並對該公司給予 “買入” 評級。一位研究分析師對該股票給予了 “強烈買入” 評級，五位分析師給予 “買入” 評級，兩位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，共識目標價為$13.17。</p>
</div><ul>
<li>LifeMD Can Surge on Its GLP-1 Offerings</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 可以憑藉其 GLP-1 產品大幅上漲</li>
</ul>
</div><p><strong>Get Our Latest Analysis on LifeMD</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 LifeMD 的最新分析</strong></p>
</div><h2>LifeMD Company Profile</h2>
<div class="lb-trans"><h2>LifeMD 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.</p>
<div class="lb-trans"><p>LifeMD, Inc 是一家直接面向患者的遠程醫療公司，連接消費者與美國的醫療專業人員以提供醫療服務。該公司提供的遠程醫療平台包括 RexMD，這是一個男性遠程醫療品牌，為各種男性健康需求提供來自持牌醫生的虛擬醫療治療；ShapiroMD 提供虛擬醫療治療、處方藥、專利醫生配方的非處方產品、外用複合藥物和治療男性和女性脱髮的醫療設備；NavaMD 是一個女性導向的遠程皮膚科，提供來自皮膚科醫生和其他提供者的虛擬醫療治療；以及處方口服和複合外用藥物用於治療衰老和痤瘡；Cleared 提供個性化的過敏、哮喘和免疫治療，包括環境和食物過敏的家庭測試、過敏和哮喘的處方以及治療慢性過敏的免疫療法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than LifeMD</li>
<li>Consumer Staples Stocks, Explained</li>
<li>How Does D-Wave Stack Up to Quantum Rivals After Earnings Season?</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Buffett Trims Apple, Bets Big on Alphabet Ahead of Retirement</li>
<li>The 3 Best Fintech Stocks to Buy Now</li>
<li>3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 LifeMD 更好</li>
<li>消費品股票解析</li>
<li>D-Wave 與量子競爭對手在財報季後的比較</li>
<li>股票交易：相對強弱指數及其用途</li>
<li>巴菲特減持蘋果，退休前大舉押注 Alphabet</li>
<li>現在購買的三隻最佳金融科技股票</li>
<li>三家能源巨頭提高股息——這對投資者意味着什麼</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZNRA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFMD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LifeMD Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 LifeMD 嗎？</h2>
</div><p>Before you consider LifeMD, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 LifeMD 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 LifeMD 並不在名單上。</p>
</div><p>While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 LifeMD 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

LifeMD（NASDAQ:LFMD）發佈了財報，每股收益比預期低 0.04 美元